Kay Washington, MD, PhD is Professor of Pathology at Vanderbilt University Medical Center and has a long-standing interest in gastrointestinal and hepatic pathology, having published over 500 scientific papers covering a wide range of topics in GI and liver disease. She received her doctorate and medical degrees from the University of North Carolina at Chapel Hill and trained in pathology at Duke University Medical Center. As Chair of the Editorial Committee for the American Joint Committee on Cancer (AJCC) from 2019 until 2023, she was charged with leading the ninth version of their Cancer Staging Manual and transforming the staging system to an electronic on-line format. She was a member of the World Health Organization Standing Editorial Board for the WHO Classification of Tumours series for the 5th series of “blue books”, serving from 2017 to 2023. Current activities include chairing the Center Guideline Committee for the College of American Pathologists (CAP); this committee oversees development of stringent evidence-based guidelines for pathology practice. She also serves on the CAP Council for Scientific Affairs and is a past member of the CAP Cancer Committee and Publications Committee. Dr. Washington is the Co-Lead for the Content Work Group for the National Cancer Institute’s Cancer PathCHART project. In addition to these activities, she has served as the Principal Investigator for over 20 years for a national biospecimen resource, the Western Division of the Cooperative Human Tissue Network, funded by the National Cancer Institute.

1.Academic Experience
1987: College of Medicine, Yonsei University, Seoul, Korea
1990: Master of Medical Science, Graduate school, College of Medicine, Yonsei Universtiy
1994: Ph.D. of Medical Science, Graduate school, College of Medicine, Yonsei University
1994: Visiting Associate, Department of Pathology, Messachusettes General Hospital, USA
1995: Visiting Fellow, Department of Pathology, Mount Sinai Medical Center, USA

2.Professional Experience
1996-present: Professor, Department of Pathology, Yonsei University College of Medicine, Seoul, Korea
2008-2012: Vice Dean of Research Affairs, Yonsei University College of Medicine
2012-2014: Vice Dean of Graduate Affairs, Yonsei University College of Medicine
2013-2017: Avison Distinguished Professor, Yonsei University College of Medicine
2016-2020: Chairman, Department of Pathology Yonsei Univesity College of Medicine

3.Societies
WHO Classification of Tumour, editorial board, responsible author (2017- present)
The Korean Academy of Science and Technology, chairman, division of medical science
The Korean Liver Cancer Association, president (2020-2021)
The National Academy of Medicine of Korea, member
Asia-Pacific Primary Liver Cancer Expert Meeting, hosting chair (2023), publication chair (2024-present)
Liver Cancer, Associate editor (2022-present)
Frontiers in Medicine, associate editor (2021- present)
Journal of Clinical Pathology (2022-present)
Hepatology, editorial board (2011-2016)
PLoS One, editorial board (2010-2014)
Gut and liver, editorial board (2012-present)
Korean Association for the Study of the Liver, council
Korean Society of Pathologists, council
American Association for the Study of Liver disease, member
United States and Canadian Academy of Pathology, member
International Liver Cancer Association, founding member
Laennec liver pathology society, member (by invitation)
The Gnomes (International Liver Pathology Group), member (by invitation)

4.Awards
Distinguished Research Awards, Yonsei University (1999, 2000, 2007, 2011).
Gegum Awards (Distinguished Research Awards), The Korean Society of Pathologists (2000).
The Best Research Awards, The Korean Society of Pathologists (2006).
The Best Research Awards, The Korean Association for the Study of the Liver (2002).
Bowon Awards (The Best Research Awards), Yonsei University (2010).
Byung Kyu Park and Byung Soo Kim Awards for Cancer Research, Yonsei University (2011).
The Best Research Awards, Yonsei University (2012).
Yuhan Academic Awards, Seoul Medical Association (2013).
Sung Jae Awards, Yonsei University (2017)
The Academic Award, The Korean Liver Cancer Association (2020)
Yonsei Award for Medicine (2023)

5.Selected papers in peer-reviewed journals (corresponding / first author)

1.Chung T, Oh S, Won J, Park J, Yoo JE, Hwang HK, Choi GH, Kang CM, Han DH, Kim S, Park YN. Genomic and transcriptomic signatures of sequential carcinogenesis from papillary neoplasm to biliary tract cancer. J Hepatol. 2025 Jan Epub ahead of print. PMID: 39832657.

2.Jang B, Kwon SM, Kim JH, Kim JM, Chung T, Yoo JE, Kim H, Calderaro J, Woo HG, Park YN. Transcriptomic profiling of intermediate cell carcinoma of the liver. Hepatol Commun. 2024;8(8):e0505

3.Jeon Y, Kwon SM, Rhee H, Yoo JE, Chung T, Woo HG, Park YN. Molecular and radiopathologic spectrum between HCC and intrahepatic cholangiocarcinoma. Hepatology. 2023;77(1):92-108.

4.Chung YS, Jeon Y, Yoo JE, Chung T, Ryu HJ, Kim H, Rhee H, Park YN. Albumin, filamin-A and cytokeratin 19 help distinguish intrahepatic cholangiocarcinoma from extrahepatic adenocarcinoma. Hepatol Int. 2023;17(1):77-85.

5.Woo HY, Rhee H, Yoo JE, Kim SH, Choi GH, Kim DY, Woo HG, Lee HS, Park YN. Lung and lymph node metastases from hepatocellular carcinoma: Comparison of pathological aspects. Liver Int. 2022;42(1):199-209.

6.Yoon JG, Kim MH, Jang M, Kim H, Hwang HK, Kang CM, Lee WJ, Kang B, Lee CK, Lee MG, Chung HC, Choi HJ, Park YN. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and PD-1/PD-L1 Blockade Responses. Hepatology. 2021;74(4):1914-1931.

7.Rhee H, Cho ES, Nahm JH, Jang M, Chung YE, Baek SE, Lee S, Kim MJ, Park MS, Han DH, Choi JY, Park YN. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications. J Hepatol. 2021;74(1):109-121.

8.Jeon Y, Yoo JE, Rhee H, Kim YJ, Il Kim G, Chung T, Yoon S, Shin B, Woo HG, Park YN. YAP inactivation in estrogen receptor alpha-positive hepatocellular carcinoma with less aggressive behavior. Exp Mol Med. 2021;53(6):1055-1067

9.Nahm JH, Lee HS, Kim H, Yim SY, Shin JH, Yoo JE, Ahn SH, Choi JS, Lee JS, Park YN. Pathological predictive factors for late recurrence of hepatocellular carcinoma in chronic liver disease. Liver Int. 2021;41(7):1662-1674

10.Kang I, Jang M, Lee JG, Han DH, Joo DJ, Kim KS, Kim MS, Choi JS, Kim SI, Park YN, Choi GH. Subclassification of Microscopic Vascular Invasion in Hepatocellular Carcinoma. Ann Surg. 2021;274(6):e1170-e1178.

11.Jee BA, Choi JH, Rhee H, Yoon S, Kwon SM, Nahm JH, Yoo JE, Jeon Y, Choi GH, Woo HG, Park YN. Dynamics of genomic, epigenomic, and transcriptomic aberrations during stepwise hepatocarcinogenesis. Cancer Res. 2019;79(21):5500-5512.

12.Rhee H, Kim HY, Choi JH, Woo HG, Yoo JE, Nahm JH, Choi JS, Park YN. Keratin 19 Expression in Hepatocellular Carcinoma Is Regulated by Fibroblast-Derived HGF via a MET-ERK1/2-AP1 and SP1 Axis. Cancer Res. 2018;78(7):1619-1631.

13.Renne SL, Woo HY, Allegra S, Rudini N, Yano H, Donadon M, Viganò L, Akiba J, Lee HS, Rhee H, Park YN, Roncalli M, Di Tommaso L. VETC (vessels encapsulating tumor clusters) is a powerful predictor of aggressive hepatocellular carcinoma. Hepatology. 2020;71(1):183-195.

14.Rhee H, Kim H, Park YN. Clinico-Radio-Pathological and Molecular Features of Hepatocellular Carcinomas with Keratin 19 Expression. Liver Cancer. 2020 Dec;9(6):663-681

15.Rhee H, An C, Kim HY Yoo JE, Park YN, Kim MJ, Hepatocellular Carcinoma with Irregular Rim-Like Arterial Phase Hyperenhancement: More Aggressive Pathologic Features. Liver Cancer. 2019;8(1):24-40.

16.Kim YJ, Yoo JE, Jeon Y, UK Chong J, Choi GH, Song DG, Jung SH, Oh BK, Park YN. Suppression of PROX1-mediated TERT expression in hepatitis B viral hepatocellular carcinoma. Int J Cancer. 2018;143(12):3155-3168.

17.Rhee H, Kim HY, Choi JH, Woo HG, Yoo JE, Nahm JH, Choi JS, Park YN. Keratin 19 Expression in Hepatocellular Carcinoma Is Regulated by Fibroblast-Derived HGF via a MET-ERK1/2-AP1 and SP1 Axis. Cancer Res. 2018;78(7):1619-1631.

18.Rhee H, Ko JE, Chung T, Jee BA, Kwon SM, Nahm JH, Seok JY, Yoo JE, Choi JS, Thorgeirsson SS, Andersen JB, Lee HS, Woo HG, Park YN. Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma. Liver Int. 2018;38(1):113-124.

19.Rhee H, Nahm JH, Kim H, Choi GH, Yoo JE, Lee HS, Koh MJ, Park YN. Poor outcome of hepatocellular carcinoma with stemness marker under hypoxia: resistance to transarterial chemoembolization. Mod Pathol. 2016;29(9):1038-49.

20.Kim MN, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, Song KJ, Park YN, Han KH. Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis. Hepatology. 2015;61(6):1851-9.

21.Kim BK, Kim HS, Yoo EJ, Oh EJ, Park JY, Kim DY, Ahn SH, Han KH, Kim SU, Park YN. Risk assessment of clinical outcomes in asian patients with chronic hepatitis B using enhanced liver fibrosis test. Hepatology. 2014;60(6):1911-9.

22.Kim SU, Jung KS, Lee S, Park JY, Kim do Y, Ahn SH, Choi GH, Kim KS, Choi JS, Han KH, Park YN. Histological subclassification of cirrhosis can predict recurrence after curative resection of hepatocellular carcinoma. Liver Int. 2014;34(7):1008-17.

23.Yoo JE, Park YN, Oh BK. PinX1, a telomere repeat-binding factor 1 (TRF1)-interacting protein, maintains telomere integrity by modulating TRF1 homeostasis, the process in which human telomerase reverse Transcriptase (hTERT) plays dual roles. J Biol Chem. 2014;289(10):6886-98.

24.Kim SU, Jung KS, Lee S, Park JY, Kim do Y, Ahn SH, Choi GH, Kim KS, Choi JS, Han KH, Park YN. Histological subclassification of cirrhosis can predict recurrence after curative resection of hepatocellular carcinoma. Liver Int. 2014;34(7):1008-17.

25.Kim H, Yoo JE, Cho JY, Oh BK, Yoon YS, Han HS, Lee HS, Jang JJ, Jeong SH, Kim JW, Park YN. Telomere length, TERT and shelterin complex proteins in hepatocellular carcinomas expressing ‘‘stemness’’-related markers. J Hepatol 2013; 59:746–752.

26.Kim SU, Oh HJ, Wanless IR, Lee S, Han KH, Park YN. The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis. J Hepatol 2012; 57(3):556-63.

27.Seok JY, Na DC, Woo HG, Roncalli M, Kwon SM, Yoo JE, Ahn EY, Kim GI, Choi J-S, Kim YB, Park YN. A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma- like gene expression trait and EMT. Hepatology 2012;55(6):1776-86.

28.Kim H, Choi GH, Na DC, Ahn EY, Kim GI, Lee JE, Cho JY, Yoo JE, Choi JS, Park YN. Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis. Hepatology 2011;54(5):1707-17.

29.Yoon SM, Gerasimidou D, Kuwahara R, Hytiroglou P, Yoo JE, Park YN, Theise ND. Epithelial Cell Adhesion Molecule (EpCAM) marks hepatocytes newly derived from stem/progenitor cells in humans. Hepatology 2011; 53:964-973.

30.Um T-H, Kim H, Oh B-K, Kim MS, Kim KS, Jung G, Park YN. Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis. J Hepatol 2011; 54: 939-947.

31.Park YN. Update on precursor and early lesions of HCC. Arch Pathol Lab Med 2011;135:704-15.

32.Oh BK, Um TH, Choi GH, Park YN. Frequent changes in subtelomeric DNA methylationpatterns and its relevance to telomere regulation during human hepatocarcinogenesis. Int J Cancer 2011;128(4):857-68.

33.Kim H, Oh B-K, Roncalli M, Park C, Yoon S-M, Yoo JE, Park YN. Large liver cell change in hepatitis B virus–related liver cirrhosis. Hepatology 2009;50(3):752-762.

34.Di Tommaso L, Destro A, Seok JY, Balladore E, Terracciano L, Sangiovanni A, Iavarone M, Colombo M, Jang JJ, Yu E, Jin SY, Morenghi E, Park YN, Roncalli M. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 2009;50(4):746-54.

35.Lee YH, Oh B-K, Yoo JE, Yoon S-M, Choi J, Kim K, Park YN. Chromosomal instability, telomere shortening, and inactivation of p21WAF1/CIP1 in dysplastic nodules of hepatitis B virus-associated multistep hepatocarcinogenesis. Modern Pathol 2009;22(8):1121-31.

36.Lee JE, Oh BK, Choi J, Park YN. Telomeric 3’overhangs in chronic HBV-related hepatitis and hepatocellular carcinoma. Int J Cancer 2008;123(2):264-272.

37.Oh BK, Kim H, Park YN, Yoo JE, Choi J, Kim KS, Lee JJ, Park C. High telomerase activity and long telomeres in advanced hepatocellular carcinomas with poor prognosis. Lab Invest 2008; 88:144–152.

38.Plentz RR, Park YN, Lechel1 A, Kim H, Nellessen F, Heike B, Langkopf E, Wilkens L, Destro A, Fiamengo B, Manns MP, Roncalli M, Rudolph KL. Telomere shortening and p21-checkpoint inactivation characterize multistep hepatocarcinogenesis in humans. Hepatology 2007; 45:968-976.

39.Park YN, Kojiro M, Di Tommaso L, Dhillon AP, Kondo F, Nakano M, Sakamoto M, Theise ND, Roncalli M and members of the Laennec Groups. Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules. Cancer 2007;109:915-923.

40.Oh BK, Kim Y-J, Park YN, Choi JS, Kim K, Park C. Quantitative assessment of hTERT mRNA expression in dysplastic nodules of HBV-related hepatocarcinogenesis. Am J Gastroenterol 2006;101:1-8.

41.Park YN, Roncalli M. Large liver cell dysplasia: a controversial entity. J Hepatol 2006;45:734-743.

42.Oh BK, Kim Y-J, Park C, Park YN. Upregulation of telomere binding proteins, TRF1, TRF2 and TIN2 is related to telomere shortening during human multistep hepatocarcinogenesis. Am J Pathol 2005;166:1-8.

Dr. Jason L. Hornick is the Director of Surgical Pathology and Immunohistochemistry and Chief of Soft Tissue and Bone Pathology at the Brigham and Women’s Hospital, Professor of Pathology at Harvard Medical School, the Mass General Brigham Endowed Cancer Chair, and a consultant at the Dana-Farber Cancer Institute. Dr. Hornick is the President of the USCAP and Past-President of the Arthur Purdy Stout Society. He was Chair of the ICCR Dataset for GIST and a member of the expert editorial boards for the 4th, 5th and 6th editions of the WHO Classification of Tumors of Soft Tissue and Bone, the Soft Tissue Sarcoma Expert Panel for the AJCC, and the Sarcoma Analysis Working Group for TCGA. Dr. Hornick serves on the Bone Cancer Panel for the NCCN and the CAP Personalized Health Care Committee; he previously chaired the USCAP Education Committee and the CAP Immunohistochemistry Committee.

Dr. Hornick is the Editor-in-Chief of the American Journal of Surgical Pathology and the Editor-in-Chief of the 5th series of the AFIP Atlases of Tumor and Non-tumor Pathology; the Editor of Practical Soft Tissue Pathology and Fletcher’s Diagnostic Histopathology of Tumors; an Associate Editor for Sternberg’s Diagnostic Surgical Pathology, Diagnostic Immunohistochemistry: Theranostic and Genomic Applications, and Advances in Anatomic Pathology; and the Consulting Editor for Surgical Pathology Clinics. He has published over 500 original papers, review articles, and book chapters. Dr. Hornick received the 2012 Arthur Purdy Stout Society Annual Prize, the 2014 Jack Yardley Investigator Award from the Gastrointestinal Pathology Society, and the 2023 Mostofi Distinguished Service Award from the USCAP. He has 22-year-old twins and sings and plays keyboards for a rock band (the Tear Downs).